CLVR

Clever Leaves HoldingsNasdaqCM:CLVR Stock Report

Market Cap

US$225.6m

7D

-8.0%

1Y

n/a

Updated

20 Sep, 2021

Data

Company Financials +
CLVR fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health4/6
Dividends0/6

CLVR Overview

Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada.

Share Price & News

How has Clever Leaves Holdings's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CLVR is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: CLVR's weekly volatility (9%) has been stable over the past year.


Market Performance


7 Day Return

-8.0%

CLVR

-2.5%

US Pharmaceuticals

-0.6%

US Market


1 Year Return

n/a

CLVR

11.0%

US Pharmaceuticals

33.8%

US Market

Return vs Industry: Insufficient data to determine how CLVR performed against the US Pharmaceuticals industry.

Return vs Market: Insufficient data to determine how CLVR performed against the US Market.


Shareholder returns

CLVRIndustryMarket
7 Day-8.0%-2.5%-0.6%
30 Day-21.4%-8.5%1.0%
90 Day-21.3%-0.2%3.4%
1 Yearn/a15.6%11.0%35.8%33.8%
3 Yearn/a20.3%10.1%60.0%50.1%
5 Yearn/a49.9%30.5%123.0%98.7%

Long-Term Price Volatility Vs. Market

How volatile is Clever Leaves Holdings's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Clever Leaves Holdings Fundamentals Summary

How do Clever Leaves Holdings's earnings and revenue compare to its market cap?
CLVR fundamental statistics
Market CapUS$225.58m
Earnings (TTM)-US$41.54m
Revenue (TTM)US$14.41m

14.4x

P/S Ratio

-5.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
CLVR income statement (TTM)
RevenueUS$14.41m
Cost of RevenueUS$5.50m
Gross ProfitUS$8.91m
ExpensesUS$50.45m
Earnings-US$41.54m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-2.19
Gross Margin61.82%
Net Profit Margin-288.24%
Debt/Equity Ratio42.7%

How did CLVR perform over the long term?

See historical performance and comparison

Valuation

Is Clever Leaves Holdings undervalued compared to its fair value and its price relative to the market?

2.63x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CLVR's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CLVR's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CLVR is unprofitable, so we can't compare its PE Ratio to the US Pharmaceuticals industry average.

PE vs Market: CLVR is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CLVR's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CLVR is good value based on its PB Ratio (2.6x) compared to the US Pharmaceuticals industry average (3.2x).


Future Growth

How is Clever Leaves Holdings forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

8.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CLVR is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CLVR is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CLVR is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CLVR's revenue (49% per year) is forecast to grow faster than the US market (9.8% per year).

High Growth Revenue: CLVR's revenue (49% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CLVR's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Clever Leaves Holdings performed over the past 5 years?

6.1%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: CLVR is currently unprofitable.

Growing Profit Margin: CLVR is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if CLVR's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare CLVR's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CLVR is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (17.5%).


Return on Equity

High ROE: CLVR has a negative Return on Equity (-37.65%), as it is currently unprofitable.


Financial Health

How is Clever Leaves Holdings's financial position?


Financial Position Analysis

Short Term Liabilities: CLVR's short term assets ($77.5M) exceed its short term liabilities ($56.6M).

Long Term Liabilities: CLVR's short term assets ($77.5M) exceed its long term liabilities ($14.4M).


Debt to Equity History and Analysis

Debt Level: CLVR's debt to equity ratio (42.7%) is considered high.

Reducing Debt: Insufficient data to determine if CLVR's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CLVR has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CLVR has sufficient cash runway for 1.3 years if free cash flow continues to reduce at historical rates of 5.9% each year.


Dividend

What is Clever Leaves Holdings's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate CLVR's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate CLVR's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CLVR's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CLVR's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CLVR's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

0.8yrs

Average management tenure


CEO

Kyle Detwiler (38 yo)

0.75

Tenure

US$191,545

Compensation

Mr. Kyle Detwiler serves as Chief Executive Officer at Clever Leaves Holdings Inc. since December 18, 2020 and also serves as its Chairman of the Board. He serves as Chairman at Ecomedics S.A.S. (formerly...


CEO Compensation Analysis

Compensation vs Market: Kyle's total compensation ($USD191.55K) is below average for companies of similar size in the US market ($USD1.10M).

Compensation vs Earnings: Kyle's compensation has been consistent with company performance over the past year.


Leadership Team

Experienced Management: CLVR's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Members

Experienced Board: CLVR's board of directors are not considered experienced ( 0.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: CLVR only recently listed within the past 12 months.


Top Shareholders

Company Information

Clever Leaves Holdings Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Clever Leaves Holdings Inc.
  • Ticker: CLVR
  • Exchange: NasdaqCM
  • Founded: NaN
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: US$225.581m
  • Shares outstanding: 26.20m
  • Website: https://www.cleverleaves.com

Number of Employees


Location

  • Clever Leaves Holdings Inc.
  • 489 Fifth Avenue
  • 27th Floor
  • New York
  • New York
  • 10017
  • United States

Listings


Biography

Clever Leaves Holdings Inc. cultivates, extracts, manufactures, and commercializes pharmaceutical-grade cannabinoid products in Colombia, Portugal, Germany, the United States, and Canada. The company opera...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/09/20 22:40
End of Day Share Price2021/09/20 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.